144 related articles for article (PubMed ID: 15682352)
1. Metabolic evaluation of HIV-infected patients receiving a regimen containing lopinavir/ritonavir (Kaletra).
Lafeuillade A; Hittinger G; Philip G; Lambry V; Jolly P; Poggi C
HIV Clin Trials; 2004; 5(6):392-8. PubMed ID: 15682352
[TBL] [Abstract][Full Text] [Related]
2. Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors.
Montes ML; Pulido F; Barros C; Condes E; Rubio R; Cepeda C; Dronda F; Antela A; Sanz J; Navas E; Miralles P; Berenguer J; Pérez S; Zapata A; González-García JJ; Peña JM; Vázquez JJ; Arribas JR
J Antimicrob Chemother; 2005 May; 55(5):800-4. PubMed ID: 15761071
[TBL] [Abstract][Full Text] [Related]
3. Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir.
González de Requena D; Blanco F; Garcia-Benayas T; Jiménez-Nácher I; González-Lahoz J; Soriano V
AIDS Patient Care STDS; 2003 Sep; 17(9):443-5. PubMed ID: 14588081
[TBL] [Abstract][Full Text] [Related]
4. [Kaletra (lopinavir/ritonavir--a new HIV protease inhibitor].
Ershov FI; Kas'ianova NV; Vasil'ev AN
Antibiot Khimioter; 2002; 47(11):27-9. PubMed ID: 12698577
[No Abstract] [Full Text] [Related]
5. Lopinavir/ritonavir combination and total/HDL cholesterol ratio.
Valerio L; Fontas E; Pradier C; Lavrut T; Garraffo R; Dunais B; Cua E; Dellamonica P
J Infect; 2005 Apr; 50(3):229-35. PubMed ID: 15780417
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
[TBL] [Abstract][Full Text] [Related]
7. Decrease in LDL size in HIV-positive adults before and after lopinavir/ritonavir-containing regimen: an index of atherogenicity?
Badiou S; Merle De Boever C; Dupuy AM; Baillat V; Cristol JP; Reynes J
Atherosclerosis; 2003 May; 168(1):107-13. PubMed ID: 12732393
[TBL] [Abstract][Full Text] [Related]
8. Lopinavir/ritonavir. (Kaletra).
Res Initiat Treat Action; 2000 Dec; 6(4):16-8. PubMed ID: 11708169
[No Abstract] [Full Text] [Related]
9. Anti-HIV agents. Lopinavir and ritonavir (Kaletra) tablets get tested.
TreatmentUpdate; 2008 Mar; 20(2):5-6. PubMed ID: 18661644
[No Abstract] [Full Text] [Related]
10. Predictive factors of hyperlipidemia in HIV-infected subjects receiving lopinavir/ritonavir.
Bongiovanni M; Bini T; Cicconi P; Landonio S; Meraviglia P; Testa L; Di Biagio A; Chiesa E; Tordato F; Biasi P; Adorni F; Monforte AD
AIDS Res Hum Retroviruses; 2006 Feb; 22(2):132-8. PubMed ID: 16478394
[TBL] [Abstract][Full Text] [Related]
11. Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens.
Gutiérrez F; Padilla S; Navarro A; Masiá M; Hernández I; Ramos J; Esteban A; Martin-Hidalgo A
J Acquir Immune Defic Syndr; 2003 Aug; 33(5):594-600. PubMed ID: 12902803
[TBL] [Abstract][Full Text] [Related]
12. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Thiry A; McGrath D;
Lancet; 2008 Aug; 372(9639):646-55. PubMed ID: 18722869
[TBL] [Abstract][Full Text] [Related]
13. Cholesterol levels in HIV-HCV infected patients treated with lopinavir/r: results from the SCOLTA project.
De Socio GV; Bonfanti P; Ricci E; Orofino G; Madeddu G; Penco G; Gianelli E; Martinelli C; Carradori S; Quirino T; Rizzardini G;
Biomed Pharmacother; 2008 Jan; 62(1):16-20. PubMed ID: 17851026
[TBL] [Abstract][Full Text] [Related]
14. Lopinavir + ritonavir tablets: new formulation. More convenient, but minimal evaluation.
Prescrire Int; 2007 Aug; 16(90):148. PubMed ID: 17724839
[TBL] [Abstract][Full Text] [Related]
15. Differences in lopinavir plasma concentrations comparing Kaletra film coated tablets and soft gelatine capsules that result in various lipid abnormalities.
Morello J; Soriano V; Blanco F; Rubio AJ; Jiménez-Nácher I; Rodríguez-Nóvoa S
Drug Metab Lett; 2009 Apr; 3(2):67-9. PubMed ID: 19601866
[TBL] [Abstract][Full Text] [Related]
16. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.
Eron JJ; Young B; Cooper DA; Youle M; Dejesus E; Andrade-Villanueva J; Workman C; Zajdenverg R; Fätkenheuer G; Berger DS; Kumar PN; Rodgers AJ; Shaughnessy MA; Walker ML; Barnard RJ; Miller MD; Dinubile MJ; Nguyen BY; Leavitt R; Xu X; Sklar P;
Lancet; 2010 Jan; 375(9712):396-407. PubMed ID: 20074791
[TBL] [Abstract][Full Text] [Related]
17. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L
AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of an anti-retroviral combination regimen including either efavirenz or lopinavir-ritonavir with a backbone of two nucleoside reverse transcriptase inhibitors.
Panagopoulos P; Tsiodras S; Antoniadou A; Katsarolis I; Papadopoulos A; Poulakou G; Giamarellou H
Clin Microbiol Infect; 2006 May; 12(5):486-9. PubMed ID: 16643529
[TBL] [Abstract][Full Text] [Related]
19. Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children.
Larrú B; Resino S; Bellón JM; de José MI; Fortuny C; Navarro ML; Gurbindo MD; Ramos JT; Soler Palacín P; Léon JA; Asensi M; Mellado MJ; Muñoz-Fernández MA
J Antimicrob Chemother; 2008 Jan; 61(1):183-90. PubMed ID: 18025025
[TBL] [Abstract][Full Text] [Related]
20. Hair loss in an HIV-1 infected woman receiving lopinavir plus ritonavir therapy as first line HAART.
Bongiovanni M; Chiesa E; Monforte Ad; Bini T
Dermatol Online J; 2003 Dec; 9(5):28. PubMed ID: 14996401
[No Abstract] [Full Text] [Related]
[Next] [New Search]
